

## ENT COOPERATION TREATY

PCT

NOTIFICATION CONCERNING  
DOCUMENT TRANSMITTED

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark  
Office  
(Box PCT)  
Washington D.C. 20231  
United States of America

in its capacity as elected Office

Date of mailing (day/month/year)

05 January 1996 (05.01.96)

International application No.

PCT/AU94/00694

International filing date (day/month/year)

11 November 1994 (11.11.94)

Applicant

THE UNIVERSITY OF SYDNEY et al

The International Bureau transmits herewith the following documents and number thereof:

\_\_\_\_\_ copy of the international preliminary examination report and annexes (Article 36(3)(a))

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

S. Mafla

Telephone No.: (41-22) 730.91.11

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark  
Office  
(Box PCT)  
Washington D.C. 20231  
United States of America

in its capacity as elected Office

Date of mailing: 03 July 1995 (03.07.95)	
International application No.: PCT/AU94/00694	Applicant's or agent's file reference: PM2540
International filing date: 11 November 1994 (11.11.94)	Priority date: 19 November 1993 (19.11.93)
Applicant: McAVOY, Johnston, William et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
16 June 1995 (16.06.95)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer:</p> <p>T. Zhao</p> <p>Telephone No.: (41-22) 730.91.11</p>
--	---

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: <b>A61K 38/16, 38/17, 38/18, 38/39, 39/395</b>	<b>A1</b>	(11) International Publication Number: <b>WO 95/13827</b> (43) International Publication Date: 26 May 1995 (26.05.95)
<p>(21) International Application Number: <b>PCT/AU94/00694</b></p> <p>(22) International Filing Date: 11 November 1994 (11.11.94)</p> <p>(30) Priority Data: PM 2540 19 November 1993 (19.11.93) AU</p> <p>(71) Applicant (for all designated States except US): THE UNIVERSITY OF SYDNEY [AU/AU]; Parramatta Road, Sydney, NSW 2006 (AU).</p> <p>(72) Inventors; and (73) Inventors/Applicants (for US only): McAVOY, Johnston, William [AU/AU]; 20 Warwick Street, Stanmore, NSW 2048 (AU). CHAMBERLAIN, Coral, Gwenda [AU/AU]; 31/26 Charles Street, Five Dock, NSW 2046 (AU).</p> <p>(74) Agent: GRIFFITH HACK &amp; CO.; GPO Box 4164, Sydney, NSW 2001 (AU).</p>	<p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).</p> <p>Published With international search report.</p>	
(54) Title: A METHOD FOR PREVENTING OR CONTROLLING CATARACT		
(57) Abstract		
<p>The present invention relates to a method for preventing or controlling pathological changes which occur in association with cataract formation in the mammalian eye by reducing the amount of or inhibiting the action of transforming growth factor-beta(TGFβ). The invention also relates to the use of inhibitors of TGFβ to prevent or minimise "aftercataract".</p>		

WO 95/13827

PCT/AU94/00694

88 Rec'd PCT/PTC 17 MAY 1995  
08/648092

## A METHOD FOR PREVENTING OR CONTROLLING CATARACT

### Technical Field

5 The present invention relates to a method for preventing or controlling pathological changes which occur in association with cataract formation in the mammalian eye by reducing the amount of or inhibiting the action of transforming growth factor-beta (TGFB). The invention also relates to the use of inhibitors of TGFB to prevent or minimise "aftercataract"

### Background Art

10 Cataract is an opacity of the lens that interferes with vision. It is one of the most common of eye diseases and, though it may occur at any time in life, it often accompanies aging. In the USA, for example, up to  
15 45% of people aged between 74 and 89 years suffer from cataract. Currently, the most commonly used treatment for cataract is surgical removal of the lens cells and subsequent implantation of a synthetic replacement lens within the remaining lens capsule. However, implantation  
20 of a synthetic lens may only temporarily restore vision because residual cells associated with the lens capsule often grow rapidly and form new opacities. The latter condition is known as "aftercataract" or post-operative capsular opacification.

25 The TGFB family consists of a group of related proteins, the most extensively studied members being TGFB1, TGFB2 and TGFB3 and it has been reported that these are all present in the eye.

### Disclosure of the Invention

30 In one aspect, the present invention provides a method of preventing or controlling cataract or cataract-like disorders in the eye of a mammalian subject which comprises administering to the subject an effective amount of one or more inhibitors of TGFB.

35 Preferably, the mammalian subject is a human being

WO 95/13827

PCT/AU94/00694

- 2 -

but the present invention is also suitable for treating cataract or cataract-like disorders in other animals such as horses, cats, dogs or the like.

Typically, the inhibitors of TGFS are selected from  
5 proteins, glycoproteins and proteoglycans.

Suitable proteins include antibodies, peptide "growth factors" such as FGF, or the like.

Suitable glycoproteins include  $\alpha_2$ -macroglobulin, laminin, collagen or the like.

10 Suitable proteoglycans include substances such as decorin, heparan sulfate proteoglycans, biglycan or the like.

In another aspect, the present invention provides an ophthalmological formulation comprising one or more  
15 inhibitors of TGFS in a pharmaceutically acceptable carrier.

In a further aspect, the present invention provides a method of preventing or controlling "aftercataract" formation in the eye of a mammalian subject following  
20 lens implant surgery which comprises implanting in the eye of the subject a lens coated with one or more TGFS inhibitors.

In yet another aspect, the present invention provides a lens implant coated with one or more TGFS  
25 inhibitors.

In yet a further aspect, the present invention provides the use of inhibitors of TGFS in the manufacture of an ophthalmological formulation for preventing or controlling cataract or cataract-like disorders.

### 30 Brief Description of Drawings

Figure 1 shows phase contrast micrographs of lens epithelial explants from 21-day-old rats cultured with TGFS2 and non-immune IgG (A,B) or with TGFS and anti-TGFS IgG (C,D). Explants were photographed after 3 days (A,C)  
35 and 5 days (B,D) of culture.

### Modes for Carrying Out the Invention

The biological activity of TGFS can be inhibited in a number of ways. One method of inhibiting the

WO 95/13827

PCT/AU94/00694

- 3 -

biological activity is by using an antibody directed against an active region of the TGF $\beta$  molecule. TGF $\beta$  biological activity can also be inhibited by the use of other molecules which sequester, inhibit or inactivate  
5 TGF $\beta$ . For example, proteoglycans such as decorin act as specific TGF $\beta$ -binding proteins.

The present inventors have shown that the aqueous and vitreous that surround the lens of the eye contain molecules that inhibit the cataract-changes induced in  
10 lens cells by TGF $\beta$  and one or more of several inhibitory molecules mentioned above have been reported to be present in the ocular media.

The TGF $\beta$  inhibitors can be administered according to the present invention either by topical application, by  
15 introduction into one or more chambers of the eye (for example, the anterior chamber), or as an intravenous injection at a site from which the inhibitors can be readily transported to the eye via the circulatory system. When the TGF $\beta$  inhibitor is  $\alpha_2$ -macroglobulin,  
20 this can also be administered by mouth or by some other suitable route other than by way of an ophthalmological preparation. For example, it may be possible to provide lens cells with elevated levels of  $\alpha_2$ -macroglobulin by administering a substance which causes an increase in  
25 serum levels of  $\alpha_2$ -macroglobulin by affecting its synthesis or breakdown or enhancing its degree of transfer into the ocular media. Molecules related to  $\alpha_2$ -macroglobulin ie, derived from it or specifically designed to mimic its TGF $\beta$  inhibitory properties but  
30 perhaps better able to pass through cellular membranes or the gut, may be administered in topical applications or by mouth or by other route.

The effective amount of the inhibitors of TGF $\beta$  required for use in the treatments according to present  
35 invention will vary with the inhibitor used, with the route of administration, the stage of condition under treatment and the host undergoing treatment, and is ultimately at the discretion of the physician.

WO 95/13827

PCT/AU94/00694

- 4 -

Typically, the TGF $\beta$  inhibitors are presented as a pharmaceutical or ophthalmological formulation. The treatment can be used as an adjunct to eye surgery to inhibit cataract-related changes that may occur as a result of surgical intervention as, for example, in the formation of "aftercataract" following implantation of synthetic lens material. The present invention may also be suitable for treatment of individuals otherwise at greater than normal risk of cataract formation or of being exposed to elevated TGF $\beta$  levels near the lens.

Most of the inhibitors of TGF $\beta$  mentioned above are commercially available.

Decorin and biglycan can be obtained by purification according to Choi et al. Note that PGI and PGII are synonyms for biglycan and decorin respectively.

Heparan sulfate proteoglycans can be obtained according to the method of Yanagishita et al.

Ophthalmological formulations of the present invention are prepared according to conventional pharmaceutical formulating techniques. The carrier may be of any form depending on the form of preparation desired for administration and the formulation may optionally contain other therapeutic ingredients. Typically, one or more inhibitors of TGF $\beta$  can be included in conventional irrigation solutions or viscoelastic solutions. Lens implants coated with one or more TGF $\beta$  inhibitors may contain other therapeutic agents and may be prepared according to conventional techniques.

#### EXAMPLE 1.

Influence of TGF $\beta$  alone and in combination with FGF on lens epithelial explants.

#### METHODS

Lens explants were prepared from both postnatal and adult rats and changes during 5 days culture with growth factor(s) were monitored by light and electron microscopy, immunolocalisation of laminin, heparan sulphate proteoglycan and fibre-specific crystallins, and crystallin ELISAs.

WO 95/13827

PCT/AU94/00694

- 5 -

Each experiment involved culturing explants for up to 5 days without added growth factors (controls), with TGF $\beta$ , with a combination of TGF $\beta$  and FGF (TGF $\beta$ /FGF), or with FGF alone. FGF is another growth factor that influences lens cell behaviour (Chamberlain and McAvoy, 1989; McAvoy et al., 1991). In some experiments, explants were prepared by a standard method used in our laboratory in which the adhering capsule serves as the substratum for the cells. In others, explants were inverted onto a laminin substratum. The latter method allows cell attachment, spreading and migration to be monitored as well as providing good visualisation of individual cells.

Bovine brain basic FGF was prepared and stored at -20°C as described by Chamberlain and McAvoy (1989). Ultrapure natural human TGF $\beta$ 1 was obtained from Genzyme (Cambridge, MA) and stored at -80°C. Working stock solutions of TGF $\beta$  and FGF were prepared (in culture medium or 1% bovine serum albumin-0.5 M NaCl in phosphate-buffered saline, respectively) and centrifuged at 10,000 g for 10 min at 4°C just before use.

Preparation and Culture of Lens Epithelial Explants:  
Standard Method

Eyes were removed from 10-day-old and 14-week-old Wistar rats under sterile conditions and placed in medium, that is, medium 199 containing bovine serum albumin and antibiotics as described by Hales et al (1992), pre-incubated at 37°C in 5% CO<sub>2</sub>/air. Lenses were removed and incubated in 2 ml medium for 45-90 min (postnatal) or 1-2 hr (adult). Epithelia were then peeled away from fibres and pinned out with the cellular surface uppermost in culture dishes containing 2 ml medium as described by McAvoy and Fernon (1984). The whole epithelium was used, unless otherwise specified, and each dish contained 2-3 explants.

Approximately 3 hr after preparation of explants, medium was replaced (1 ml/dish) and 10  $\mu$ l samples of stock solutions of TGF $\beta$  and/or FGF were added, as



WO 95/13827

PCT/AU94/00694

- 6 -

required, to give final concentrations of 20 and 40 ng/ml, respectively. Explants were cultured for 5 days with daily monitoring by phase contrast microscopy. At appropriate times explants were processed for light or electron microscopy as described below. Alternatively, to assess the accumulation of fibre-specific crystallins, at the end of the culture period, explants were placed in 10 mM EDTA-0.02% Triton X-100, pH 10 (two explants in 200  $\mu$ l) and stored at -20°C, then used for  $\beta$ - and  $\gamma$ -crystallin ELISAs with standards ranging from 0-20 ng/well.

Preparation and Culture of Lens Epithelial Explants; on Laminin Substratum

This method is as described by Hales et al (1992). Briefly, on the day before the experiment, culture dishes were pre-coated with laminin. Whole explants were then prepared as described above, but with the cellular surface placed face down on the laminin and using lenses from 21-day-old rats; explants from rats of this age show a strong migratory response to FGF (unpublished observation). Each dish contained three explants. Growth factor treatments and culture conditions were as described for standard explants, except that a lower concentration of FGF, 2 ng/ml, was used to ensure that the main response to FGF alone was cellular migration rather than fibre differentiation. Responses were monitored daily by phase contrast microscopy.

Microscopy

Explants used for immunofluorescent localisation were collected at the end of the culture period, fixed in Carnoy's fixative for 20 min at room temperature, transferred to 70% ethanol, then covered with a drop of melted 2.5% agar, before dehydrating in ethanol and embedding in paraffin. Sections were cut perpendicular to the explant surface and stained with haematoxylin-phloxine or used for immunolocalisation of laminin, heparan sulphate proteoglycan (HSPG) or  $\beta$ - and  $\gamma$ -crystallins. For each antibody and each explant 20-30

WO 95/13827

PCT/AU94/00694

- 7 -

sections cut through the central region were examined, and at least two explants were processed for each growth factor treatment. Controls for non-specific fluorescence were included routinely, that is, sections were treated with non-immune rabbit serum instead of specific antibody. For whole mounts, explants were fixed in the culture dish with 100% ethanol and stained with haematoxylin-phloxine.

For ultrastructural studies, explants from 10-day-old rats were processed for transmission electron microscopy (TEM) and for scanning electron microscopy (SEM) as described by Lovicu and McAvoy (1992); explants were collected at 3 or 5 days of culture. Explants from adult rats were processed for SEM only at 5 days. For both SEM and TEM, at least two explants were viewed for each treatment and, for TEM, 20-30 grids were viewed per explant.

#### RESULTS

Epithelial explants from postnatal rats (10 and 21 days old) were used for initial detailed studies. Because of the unusual nature of the observed responses to TGF $\beta$ , a brief comparative study was then carried out using explants from adult rats.

#### Lens Explants from 10-day-old Rats; Standard Method

Phase contrast microscopy and SEM. In control and TGF $\beta$ -treated explants the cells retained a characteristic epithelial cell morphology throughout the culture period, that is, they were present in a monolayer with cobblestone-like packing. In both cases, some cell debris was detected on the monolayer surface. In TGF $\beta$ -treated explants only, single cells or small groups of cells were also occasionally detected on the monolayer surface. SEM of explants cultured for 5 days showed that the apical surface of some cells in TGF $\beta$ -treated explants overlapped onto neighbouring cells.

TGF $\beta$ /FGF- and FGF-treated explants were clearly distinguishable from controls within the first day of culture and indistinguishable from each other at this

WO 95/13827

PCT/AU94/00694

- 8 -

stage. Cells were irregularly packed and intercellular spaces were common, an explant morphology that is generally associated with active cell migration (McAvoy and Chamberlain, 1989; McAvoy, 1990). After 2 days culture some cells in the TGF $\beta$ /FGF-treated, but not in the FGF-treated, explants were extensively elongated. The number of elongated cells varied between explants; they generally formed only a small proportion of the cellular population but because they often formed regular rows they were quite distinct from the other cells in the explant which appeared similar to those in the FGF-treated explants. This marked difference between treatments was even more apparent at 3 days culture due to more cells becoming extensively elongated in TGF $\beta$ /FGF-treated explants. At this stage SEM showed that many of the elongated cells were attached to neighbouring cells at multiple sites along their length.

By 4 and 5 days culture, most of the cells in TGF $\beta$ /FGF-treated explants were in multilayers and all these explants had developed several regions where the cells were arranged in rosettes with elongated cells radiating out in a circular array from a focal point. Outside these rosettes, which occupied up to about 50% of the explant surface, there were some areas where similar extensively elongated cells were arranged in parallel arrays. Remaining cells were less elongated and appeared irregularly arrayed as in FGF-treated explants.

SEM showed that, in regions outside the rosettes and parallel arrays of extensively elongated cells, cells had numerous interlocking processes and appeared similar to the early differentiating fibres seen in explants treated with FGF alone. The morphological changes in explants from 10-day-old rats undergoing fibre differentiation in response to this concentration of FGF have been reported in detail elsewhere (Lovicu and McAvoy, 1992); multilayering and the formation of numerous interlocking processes are well-established features of this process (Lovicu and McAvoy, 1992; Lovicu and McAvoy, 1989). In

WO 95/13827

PCT/AU94/00694

- 9 -

the FGF/TGFB-treated explants, occasional patches of fibrillar extracellular matrix (ECM)-like material were noted on the explant surface. This matrix was dense and obscured the cells below.

5 TEM. Cells in explants cultured with FGF and TGFB/FGF for 5 days became multilayered and exhibited features of early fibre differentiation including elongation, sparse cytoplasmic organelles and nucleolar RNA particle aggregations; ball-and-socket joints typical of fibre  
10 differentiation were also detected. Additionally in TGFB/FGF-treated explants, cells exhibiting margination or chromatin and cytoplasmic condensation were common, and membrane-bound cellular fragments and electron-dense bodies resembling secondary lysosomes were found within  
15 many cells that otherwise appeared normal. These features are characteristic of apoptosis or programmed cell death (Wyllie et al. 1980; Williams et al., 1992). Similar apoptotic changes were also detected in TGFB/FGF-treated explants at 3 days.

20 Pockets of ECM-like granular material were commonly detected between cells (and sometimes appeared to be within cells) in TGFB/FGF-treated explants. Often near the cell membrane this material was present in a laminar arrangement and coated pits and vesicles were common in  
25 such regions. Cells with prominent rough endoplasmic reticulum and Golgi, which also usually showed abundant arrays of microfilaments, were also found frequently in these explants.

In explants cultured with TGFB alone, the epithelial  
30 cells remained in a monolayer and were similar to controls except that, in the presence of TGFB, spaces were often present between cells. This, together with the overlapping of cells suggests that TGFB may be causing some disturbance of cell-cell interactions.

35 Immunohistochemical localisation of laminin and HSPG. The ECM molecules laminin and HSPG are both found in the normal lens capsule (Parmigiani and McAvoy, 1991; Mohan and Spiro, 1986) and, as expected, reactivity for both

WO 95/13827

PCT/AU94/00694

- 10 -

laminin and HSPG was detected in the capsule in all explants irrespective of treatment.

In TGFB/FGF-treated explants, reactivity for both laminin and HSPG was also localised within the explant in sites that were approximately similar in size and distribution to the pockets of ECM-like material seen by TEM. In FGF-treated explants, a few such regions were also detected; however, these were generally smaller and not as numerous as in explants treated with both growth factors. More sites exhibited reactivity for laminin than for HSPG and generally laminin reactivity was stronger.

In controls and TGFB-treated explants no pockets of reactivity for laminin or HSPG were detected within the cellular layer. Thus the intercellular spaces revealed by TEM in TGFB-treated explants did not contain ECM.

$\beta$ -crystallin accumulation. To assess fibre differentiation we measured the fibre-specific  $\beta$ - and  $\gamma$ -crystallin content of explants at the end of the 5 day culture period by ELISA. Significant  $\beta$ -crystallin accumulation occurred only in explants cultured with TGFB/FGF or FGF ( $P = 0.001$ , compared with control); an apparent enhancement of  $\beta$ -crystallin accumulation in TGFB/FGF-treated explants relative to the FGF-treated explants did not reach statistical significance. None of the treatments induced significant accumulation of  $\gamma$ -crystallin within the 5 day culture period.

Complementary immunolocalisation studies confirmed these findings and revealed that  $\beta$ -crystallin appeared to be distributed throughout most cells in both TGFB/FGF- and FGF-treated explants.

#### Lens Explants from 21-day-old Rats: on Laminin Substratum

When explants were cultured cell surface down on a laminin substratum without growth factors, cells spread and migrated off the capsule onto the substratum forming an annulus around the explant. This process continued over the 5 day culture period and was significantly enhanced by FGF (Hales et al., 1992). The addition of TGFB, however, inhibited spreading and migration to the

WO 95/13827

PCT/AU94/00694

- 11 -

presence or absence of FGF so that a full annulus of cells did not develop; there were only a few isolated outgrowths of cells around the explant perimeter, and spreading and migration appeared to cease after 2 days of culture. This is consistent with the observation that the cells at the leading edge of these outgrowths had few of the pseudopodia characteristic of rapidly migrating cells seen in FGF-treated explants at 2 days. There was no apparent difference between TGF $\beta$ - and TGF $\beta$ /FGF-treated explants throughout the culture period.

During the first day of culture, all the cells in TGF $\beta$  treated explants (that is, with or without FGF) had a morphology very similar to those in controls; however, by day 2 most of the cells that had spread onto the laminin substratum had become substantially elongated, some to the extent of being spindle-shaped or needle-like. In some regions cells that remained under the capsule also become elongated and aligned; these regions tended to extend between islands of epithelial-like cells. By 3 days of culture, explants treated with TGF $\beta$  mostly consisted of elongated cells and under the capsule differences between the peripheral and central regions of the explants became detectable. The periphery was well populated with multilayers of aligned elongated cells, whereas cells in the central region were in reticular arrangements exposing regions of bare capsule.

Wrinkling of the capsule was noted in all explants cultured with TGF $\beta$  under these explant conditions. The wrinkles had a reticular arrangement and were primarily located in the central region of the explant. The wrinkles were most obvious at 2 days and generally became less pronounced during the remainder of the 5 day culture period.

Cell loss also appeared to be a major feature of explants exposed to TGF $\beta$ . Bare patches of capsule were initially detected in the central region of the explant at 3 days and condensed nuclei were readily visible in cells that had spread onto the laminin. Cell numbers then

WO 95/13827

PCT/AU94/00694

- 12 -

progressively decreased and by 5 days the majority of the cells had been lost from the explant; the remaining cells retained the reticular arrangement first observed at 3 days.

5 Lens Explants from Adult Rats: Standard Method

Phase contrast and SEM. The morphological changes observed by phase contrast microscopy in these experiments were essentially similar to those reported for the explants from 21-day old rats cultured on laminin, although as expected under these culture conditions no cells migrated off the capsule. Throughout the culture period there were no clear differences between TGF $\beta$ - and TGF $\beta$ /FGF-treated explants. During day 1, explants cultured with TGF $\beta$  retained the cobblestone appearance characteristic of controls, but by 2 days many of the cells had elongated. Bare patches of capsule were detected at 3 days and these increased progressively during the culture period.

The latter finding was confirmed by SEM at 5 days which also revealed that the morphology of cells that remained in explants cultured with TGF $\beta$  for 5 days was variable. Often cells were present in reticular arrays which seemed to consist mainly of mosaics of cells many of them epithelial-like. In other regions many cells were elongated and distinctly spindle- or needle-like and in some of these the cellular surface was covered with fine blebs. In the explant periphery, where more cells tended to survive, they were often present either as multilayers of smooth surfaced spindle-shaped cells or as more rounded cells with distinct surface blebbing typical of cells undergoing apoptotic cell death (Wyllie et al., 1980; Williams et al., 1992).

In FGF-treated explants, most cells retained an epithelial morphology although in the periphery some cells showed slight elongation characteristic of early fibre differentiation (Lovicu and McAvoy, 1992). Controls stayed as an epithelial monolayer throughout the culture period.

WO 95/13827

PCT/AU94/00694

- 13 -

Immunohistochemical localisation studies. The pockets of laminin or HSPG reactivity reported above were not detected in explants from adult rats examined at the end of the culture period, irrespective of treatment.

- 5 Reactivity for  $\beta$ -crystallin was detected in some cells interspersed throughout the explant in controls and FGF-treated explants; in both TGF $\beta$  and TGF $\beta$ /FGF-treated explants the clumps of cells that survived for 5 days also included some cells that fluoresced for  $\beta$ -  
10 crystallin. No  $\gamma$ -crystallin was detected in any of the explants. There was thus no evidence that any of the treatments stimulated ECM production or fibre-specific crystallin accumulation during the 5 day culture period.

#### SUMMARY

- 15 TGF $\beta$  induced cells in explants to undergo an extensive and rapid elongation which had features that distinguished it from FGF-induced fibre differentiation. TGF $\beta$  also induced accumulation of extracellular matrix, capsule wrinkling, cell death by apoptosis and  
20 distinctive arrangements of cells. These TGF $\beta$ -induced responses are characteristic of the changes reported to occur during formation of various types of cataracts (Novotny and Pau, 1984; Eshagian, 1982; Eshagian and Streeten, 1980; Green and McDonnell, 1985). Standard  
25 explants from 10-day-old rats responded to TGF $\beta$  only in the presence of FGF. Comparable explants from adult rats, or from 21-day-old rats cultured on a laminin substratum, responded readily to TGF $\beta$  whether or not FGF was present.

#### 30 EXAMPLE 2

Detailed description of an explant study using an antibody against TGF $\beta$  to inhibit TGF $\beta$ -induced cataract-like changes.

#### METHOD

- 35 Lens epithelial explants (2 per culture dish) were prepared from 21-day-old rats and trimmed to remove the peripheral region as described elsewhere (See Example 1, Standard Method). Explants were preincubated in culture



WO 95/13827

PCT/AU94/00694

- 14 -

medium at 37°C in 5% CO<sub>2</sub>/air for approximately 3 hours before use.

A pan-specific polyclonal antibody against TGFβ (rabbit IgG; British Bio-technology, Abingdon, UK; Cat. No. BDA 47,) was used; this neutralises TGFβ1, β1.2, β2, β3, and β5. This IgG and non-immune rabbit IgG were reconstituted in sterile phosphate-buffered saline to a concentration of 3 mg IgG/ml.

TGFβ2 (Genzyme, Cambridge, MA) was diluted with sterile medium to a concentration of 0.25 ng/10 μl. Under sterile conditions, 33 μl immune or non-immune IgG solution was mixed with 20 μl TGFβ2 stock solution and 47 μl medium, incubated at 37°C in 5% CO<sub>2</sub>/air for 30 min, then diluted to 2 ml with medium. Preincubation medium was removed from two culture dishes and 1 ml TGFβ-IgG mixture was added to each. All explants were cultured for 5 days with daily monitoring by phase contrast microscopy. Explants cultured with non-immune IgG served as controls for any effects of IgG itself on TGFβ activity.

Figure 1 shows phase contrast micrographs of lens epithelial explants from 21-day-old rats cultured with TGFβ2 and non-immune IgG (A,B) or with TGFβ and anti-TGFβ IgG (C,D). Explants were photographed after 3 days (A,C) and 5 days (B,D) of culture. TGFβ induces extensive elongation of cells (A, arrow); subsequently many cells are lost exposing regions of capsule which show wrinkles (B, arrow). Anti-TGFβ completely blocks these changes and epithelial cells remain in a normal closely packed cobble-stone arrangement (C,D). The final concentrations of TGFβ and IgG were 0.25 ng/ml and 50 μg/ml, respectively.

#### RESULTS

In the presence of non-immune IgG, TGFβ induced rapid elongation which occurred within 2-3 days (Fig. 1A) and by 5 days cells had been lost from the explant revealing wrinkling of the underlying capsule (Fig. 1B). These changes are typical of changes described in detail

WO 95/13827

PCT/AU94/00624

- 15 -

in Example 1 for explants cultured with TGF $\beta$  in the absence of IgG.

In the presence of anti-TGF $\beta$ , these changes were completely blocked. Throughout the 5 day culture period the explants retained their original epithelial-like morphology (Fig. 1C, D) and were indistinguishable from explants cultured in medium alone.

### EXAMPLE 3

Detailed description of an explant study using aqueous and vitreous to inhibit TGF $\beta$ -induced cataract like changes

### METHOD

Aqueous and vitreous were obtained from the eyes of freshly slaughtered 2 to 3 year-old-cattle as follows. Immediately on removal of the eye, the aqueous (about 1.5 ml) was collected using a sterile syringe fitted with a 23 gauge needle and an incision was made around the cornea to gain access to the lens. After carefully removing adhering iris, the lens was lifted out and the vitreous adjacent to the lens, mainly liquid vitreous, was collected (2-3 ml) using a syringe without needle and taking care to avoid contamination with retina. The whole procedure was completed within about 1 hour of the death of the animals. Samples were transported to the laboratory on ice and used as soon as possible.

Lens epithelial explants (2 per culture dish) were prepared from 21-day-old rats as described previously (See Example 1, Standard Method). Samples of aqueous or vitreous were diluted with an equal volume of sterile culture medium (defined in Example 1), using repeated passage through a 23 gauge needle to ensure thorough mixing. These mixtures were equilibrated at 37°C for 30 minutes in 5% CO<sub>2</sub>/air before use. Stock solutions containing 25 or 100 pg/10 $\mu$ l TGF $\beta$ 2 (Genzyme, Cambridge, MA) were prepared in sterile medium. Nine treatment groups were then set up by replacing medium in culture dishes containing explants with 1 ml medium or diluted aqueous or vitreous, with or without added TGF $\beta$ , as

WO 95/13827

PCT/AU94/00694

- 16 -

indicated in Table 1. Explants were cultured and monitored for cataract-like changes by phase contrast microscopy. In particular, each explant was graded according to the extent of spindle-like elongation and cell death, which are characteristically observed in explants cultured with TGF $\beta$  (See Examples 1 and 2). Explants were photographed on day 4.

### RESULTS

No significant changes were observed for any treatment on day 1; explants retained typical epithelial morphology. Explants cultured with medium alone did not change throughout the culture period. With continuing culture, explants cultured with TGF $\beta$  showed typical cataract-like changes, with more cell death for 100 pg/ml than 25 pg/ml (Table 1). Aqueous virtually completely inhibited the effects of 25 pg/ml TGF $\beta$  and partially inhibited the effects of 100 pg/ml. (With or without TGF $\beta$ , aqueous also caused some shrivelling of the capsule.) Explants cultured with vitreous, with or without TGF $\beta$ , showed changes typical of early fibre differentiation (cf. Schulz et al., 1993), but there was no evidence of cataract-like changes; vitreous thus completely inhibited the cataract-like changes induced by TGF $\beta$ .

Table 1. Inhibition of TGF $\beta$ -induced cataract-like changes in rat lens epithelial explants by aqueous and vitreous

Treatment	TGF $\beta$ 2 concentration (pg/ml)		
	0	25	100
Day 3:			
Culture medium	-	+++/††	++++/††
Aqueous	-	-	++/††
Vitreous	fd	fd	fd

WO 95/13827

PCI/AU94/00694

- 17 -

## Day 4:

Culture medium	-	o/↑↑↑↑	o/↑↑↑↑
Aqueous	-	-	o/↑↑↑↑
Vitreous	fd	fd	fd

5

## Day 5:

Culture medium	-	o/↑↑↑↑	o/↑↑↑↑
Aqueous	-	-	o/↑↑↑↑
Vitreous	fd	fd	fd

10 Explants were cultured with medium or with diluted aqueous or vitreous, with or without the addition of TGF $\beta$ , as indicated. Four explants were subjected to each treatment. Code: -, negligible change; + - + + +, indicates extent of spindle-like elongation; ↑ - ↑↑↑, indicates extent of cell loss; o, elongation assessment was invalidated by cell loss; fd, changes typical of early fibre differentiation with no cataract-like changes.

SIGNIFICANCE

20 This study indicates that the aqueous and vitreous that surround the lens of the eye contain molecules that inhibit the cataract-like changes induced in lens cells by TGF $\beta$ . This effect may be due to the presence of one or more of several different kinds of inhibitory molecules which have been reported to be present in

25 aqueous and vitreous: e.g. serum proteins, such as  $\alpha_2$ -macroglobulin; proteoglycans, such as decorin or heparan sulphate proteoglycans; or other peptide 'growth factors' such as FGF. All these molecules have been reported to bind to and/or inhibit TGF $\beta$  activity (LaMarre et al.,

30 1991; Yamaguchi et al., 1992; McCaffrey et al., 1992; Hales et al., in press).  $\alpha_2$ -macroglobulin is synthesised by the cornea (Twining et al. 1994) and is present in the aqueous (Ando et al., 1993); it probably enters the aqueous and vitreous along with other serum proteins

35 found in these media (see, for example, Beebe et al., 1986). It has been shown that decorin is present near the

WO 95/13827

PCT/AU94/00694

- 18 -

lens in proliferative vitreoretinopathy (Hagedorn et al., 1993). Heparan sulphate is present in the vitreous, probably in association with extracellular matrix proteoglycans (Kamei et al., 1992). FGF is reported to be present in vitreous, and in much lower amounts in aqueous (Schulz et al., 1993), and to suppress the formation of TGF $\beta$ -induced spindle-cell formation in lens explants (Hales et al, in press). Other molecules known to bind to TGF $\beta$  and/or inhibit its activity, which may be contributing to the observed inhibitory effects of aqueous and/or vitreous, include biglycan (Yamaguchi et al., 1990), laminin and collagen (Paralkar et al., 1991).

#### EXAMPLE 4

Detailed description of an explant study using  $\alpha_2$ -macroglobulin to inhibit TGF $\beta$ -induced cataract-like changes

#### METHOD

$\alpha_2$ -macroglobulin prepared from bovine plasma was obtained from Doehringer Mannheim Australia (Castle Hill, NSW; #602 442). Lens epithelial explants (2 per culture dish) were prepared from 21-day-old rats as described previously (See Example 1, Standard Method).  $\alpha_2$ -macroglobulin was dissolved in culture medium (defined in Example 1) at a final concentration of 400  $\mu$ g/ml. The solution was sterilised by passing through a 0.22  $\mu$ m filter and a portion was diluted with an equal volume of sterile medium. These solutions were equilibrated at 37°C in 5% CO $_2$ /air before use. A stock solution containing 25 pg/10 $\mu$ l TGF $\beta$ 2 (Genzyme, Cambridge, MA) was prepared in sterile medium. Six treatment groups were then set up by replacing medium in culture dishes containing explants with 1 ml medium or 1 ml medium containing 200 or 400  $\mu$ g/ml  $\alpha_2$ -macroglobulin, with or without added TGF $\beta$ , as indicated in Table 2. Explants were cultured and monitored for cataract-like changes by phase contrast microscopy. In particular, each explant was graded according to the extent of spindle-like elongation and cell death, which are characteristically observed in

WO 95/13827

PCT/AU94/00694

- 19 -

explants cultured with TGF $\beta$  (See Examples 1 and 2).  
Explants were photographed on days 3-5.

Table 2. Inhibition of TGF $\beta$ -induced cataract-like changes  
in rat lens epithelial explants by  $\alpha_2$ -  
macroglobulin

5 macroglobulin

Treatment	TGF $\beta$ 2 concentration (pg/ml)	
	0	25

Day 2:

10 Culture medium

+

$\alpha_2$ -MG, 200  $\mu$ g/ml

-

-

$\alpha_2$ -MG, 400  $\mu$ g/ml

-

-

Day 3:

15 Culture medium

-

+++/ $\dagger$

$\alpha_2$ -MG, 200  $\mu$ g/ml

-

+

$\alpha_2$ -MG, 400  $\mu$ g/ml

-

+

Day 4:

20 Culture medium

-

o/++++

$\alpha_2$ -MG, 200  $\mu$ g/ml

-

+/ $\dagger$

$\alpha_2$ -MG, 400  $\mu$ g/ml

-

+/ $\dagger$

Day 5:

Culture medium

-

o/++++

$\alpha_2$ -MG, 200  $\mu$ g/ml

-

-/ $\dagger$

$\alpha_2$ -MG, 400  $\mu$ g/ml

-

-/ $\dagger$

25 Explants were cultured with medium, with or without the addition of  $\alpha_2$ -macroglobulin ( $\alpha_2$ -MG) and/or TGF $\beta$ , as indicated. Four explants were subjected to each treatment. Code: -, negligible change or reverted to predominantly epithelial morphology; + - +++, indicates extent of spindle-like elongation;  $\dagger$  - + $\dagger$ ttt, indicates extent of cell loss; o, elongation assessment

30

WO 95/13827

PCT/AU94/00694

- 20 -

was invalidated by cell loss.

### RESULTS

No significant changes were observed in explants cultured with medium alone or with medium containing  $\alpha_2$ -macroglobulin; the explants retained typical epithelial morphology throughout the culture period. On days 2-5, explants cultured with TGF $\beta$  showed typical cataract-like changes (Table 2). The TGF $\beta$ -induced changes were substantially inhibited by including  $\alpha_2$ -macroglobulin in the medium.

### References

1. Chamberlain CG, McAvoy JW. Induction of lens fibre differentiation by acidic and basic fibroblast growth factor (FGF). *Growth Factors*. 1989;1:125-134.
- 15 2. McAvoy JW, Chamberlain CC. Fibroblast growth factor (FGF) induces different responses in lens epithelial cells depending on its concentration. *Development*. 1989;107:221-228.
3. McAvoy JW, Chamberlain CG, de Iongh RU, Richardson NA, Lovicu FJ. The role of fibroblast growth factor in eye lens development. *Ann NY Acad Sci*. 1991;638:256-274.
- 20 4. Hales A, Chamberlain CG, McAvoy JW. Measurement of lens epithelial cell migration on a laminin substratum using image analysis. *J Comput Assist Microscopy*. 1992;4:135-139.
- 25 5. McAvoy JW, Fernon VTP. Neural retinas promote cell division and fibre differentiation in lens epithelial explants. *Curr Eye Res*. 1984;3:827-834.
6. Parmigiani CM, McAvoy JW. The roles of laminin and fibronectin in the development of the lens capsule. *Curr Eye Res*. 1991;10:501-511.
- 30 7. Lovicu FJ, McAvoy JW. The age of rats affects the response of lens epithelial explants to fibroblast growth factor - an ultrastructural analysis. *Invest Ophthalmol Visual Sci*. 1992;33:2269-2278.
- 35 8. McAvoy JW. Cell lineage analysis of lens epithelial cells induced to differentiate into fibres. *Exp Eye Res*.

WO 95/13827

PCT/AU94/00694

- 21 -

1988;47:869-883.

9. Lovicu FJ, McAvoy JW. Structural analysis of lens epithelial explants induced to differentiate into fibres by fibroblast growth factor (FGF). *Exp Eye Res.* 1989;49:479-494.
10. Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. *Internat Rev Cytol.* 1980;68:251-299.
11. Williams GT, Smith AS, McCarthy NJ, Grimes EA. Apoptosis: final control point in cell biology. *Trends Cell Biol.* 1992;2:263-267.
12. Mohan PS, Spiro RG. Macromolecular organization of basement membranes. Characterization and comparison of glomerular basement membrane and lens capsule components by immunochemical and lectin affinity procedures. *J Biol Chem.* 1986;261:4328-4336.
13. Novotny CEK, Pau H. Myofibroblast-like cells in human anterior capsular cataract. *Virchows Arch [Pathol Anat]*. 1984;404:393-401.
14. Eshagian J. Human posterior subcapsular cataracts. *Trans Ophthal Soc UK.* 1982;102:364-368.
15. Eshagian J, Streeten B. Human posterior subcapsular cataract - an ultrastructural study of the posteriorly migrating cells. *Arch Ophthalmol.* 1980;98:134-143.
16. Green WR, McDonnell PJ. Opacification of the posterior capsule. *Trans Ophthalmol Soc UK.* 1985;104:727-739.
17. Schulz MW, Chamberlain CG, de Iongh RU, McAvoy JW. Acidic and basic FGF in ocular media and lens: implications for lens polarity and growth patterns. *Development* 1993;118:117-126.
18. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of TGF $\beta$  by the proteoglycan decorin. *Nature.* 1990;346:281-284.
19. McCaffrey TA, Falcone DJ, Du B. TGF $\beta$ 1 is a heparan-binding protein: identification of putative heparan-binding regions and isolation of heparans with varying affinities for TGF $\beta$ 1. *J. Cell. Physiol.*



WO 95/13827

PCT/AU94/00694

- 22 -

1992;152:430-440.

20. Hales AM, Schulz MW, Chamberlain CG, McAvoy JM. TGF- $\beta$ 1 induces lens cells to accumulate  $\alpha$ -smooth muscle actin, a marker for subcapsular cataracts. *Curr Eye Res.*, in press.

21. Twining SS, Fukuchi T, Yue BYJT, Wilson PM, Zhou X, Loushin G.  $\alpha_2$ -macroglobulin is present in and synthesised by the cornea. *Invest. Ophthalmol. Vis. Sci.* 1994;35:3226-3233.

22. Beebe DC, Latker CH, Jebens HAH, Johnson MC, Feagans DE, Feinberg RN. Transport and steady-state concentrations of plasma proteins in the vitreous humor of the chicken embryo: Implications for the mechanism of eye growth during early development. *Dev Biol.* 1986;114:361-368.

23. Ando H, Twining SS, Yue BYJT, Zhou X, Fini ME, Kaiya T, Higginbottom EJ, Sugar J. MMPs and proteinase inhibitors in the human aqueous humour. *Invest. Ophthalmol. Vis. Sci.* 1993;34:3541-3548.

24. Hagedorn M, Esser P, Wiedeman P, Heilmann K. Tenascin and decorin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy. *German J Ophthalmol.* 1993;2:28-31.

25. Kamei A, Totani A. Isolation and characterisation of minor glycosaminoglycans in the rabbit vitreous. *Biochem Biophys Res Comm.* 1982;109:881-887.

26. Paralkar VM, Vukicevic S, Reddi AH. TGF $\beta$  binds collagen type IV of basement membrane matrix: implications for development. *Dev. Biol.* 1991;143:303-308.

27. LaMarre J, Wollenberg GK, Gonias SL, Hayes MA. Cytokine binding and clearance properties of proteinase-activated  $\alpha_2$ -macroglobulins. *Lab Invest.* 1991;65:3-14.

28. Choi HU, Johnson TL, Pal S, Tang L-H, Rosenberg L and Neame PJ. Characterisation of the dermatan sulfate proteoglycans, DS-PGI and DS-PGII, from bovine articular cartilage and skin isolated by octyl-Sepharose

WO 95/13827

PCT/AU94/00694

- 23 -

chromatography. *J. Biol. Chem.* 1989; 264:2876-2884.

29. Yanagishita M, Midura RJ and Hascall VC.  
Proteoglycans: Isolation and purification from tissue  
culture. *Methods in Enzymology* 1987 139:279 289.

WO 95/13827

PCT/AU94/00694

- 24 -

## Claims

1. A method of preventing or controlling cataract or cataract-like disorders in the eye of a mammalian subject which comprises administering to the subject an effective amount of one or more inhibitors of TGF $\beta$ .
2. A method according to claim 1 wherein the one or more inhibitors of TGF $\beta$  are selected from proteins, glycoproteins and proteoglycans.
3. A method according to claim 2 wherein the protein inhibitors of TGF $\beta$  are selected from antibodies and peptide growth factors.
4. A method according to claim 2 wherein the glycoprotein inhibitors of TGF $\beta$  are selected from  $\alpha_2$ -macroglobulin, laminin and collagen.
5. A method according to claim 2 wherein the proteoglycan inhibitors of TGF $\beta$  are selected from decorin, heparan sulfate proteoglycans and biglycan.
6. An ophthalmological formulation comprising one or more inhibitors of TGF $\beta$  in a pharmaceutically acceptable carrier.
7. An ophthalmological formulation according to claim 6 wherein the inhibitors of TGF $\beta$  are as defined in claim 2, 3, 4 or 5.
8. A method of preventing or controlling "aftercataract" formation in the eye of a mammalian subject following lens implant surgery which comprises implanting in the eye of the subject a lens coated with one or more TGF $\beta$  inhibitors.
9. A method according to claim 8 wherein the TGF $\beta$  inhibitors are as defined in claim 2, 3, 4 or 5.
10. A lens implant coated with one or more TGF $\beta$  inhibitors.
11. A lens implant according to claim 10 coated with one or more TGF $\beta$  inhibitors as defined in claim 2, 3, 4 or 5.
12. The use of inhibitors of TGF $\beta$  in the manufacture of an ophthalmological formulation for preventing or controlling cataract or cataract-like disorders.

WO 95/13827

PCT/AU94/00694

- 25 -

13. Use according to claim 12 wherein the TGF $\beta$  inhibitors are as defined in claim 2, 3, 4 or 5.

WO 95/13827

PCT/AU94/00694

1/1




Fig. 1A



Fig. 1B




Fig. 1C





Fig. 1D

FIGURE 1

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int. Cl. <sup>6</sup> A61K 38/16, 38/17, 38/18, 38/39, 39/395  According to International Patent Classification (IPC) or to both national classification and IPC					
<b>B. FIELDS SEARCHED</b>  Minimum documentation searched (classification system followed by classification symbols) IPC A61K  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AUP:IPC as above  Electronic data base consulted during the international search (name of data base, and where practicable, search terms used) WPAT:- TGF, transforming growth factor, CIF, cartilage inducing factor CASM:- as above.					
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>					
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.			
P,X	WO,A, 94/10187 (HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP et al) 11 May 1994 (11.05.94).	6-7, 12-13			
P,X	WO,A, 94/09815 (CELTRIX PHARMACEUTICALS INC) 11 May 1994 (11.05.94), see page 20 line 35	6-7, 12-13			
P,X	WO,A, 94/01124 (CELTRIX PHARMACEUTICALS INC) 20 January 1994 (20.01.94) see page 1 lines 8-22, page 21 lines 28-36	1-3, 6-7, 12-13,			
<div style="display: flex; justify-content: space-between;"> <div> <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.         </div> <div> <input checked="" type="checkbox"/> See patent family annex.         </div> </div>					
<table style="width: 100%; border: none;"> <tr> <td style="width: 33%; vertical-align: top;">           * Special categories of cited documents :            "A" document defining the general state of the art which is not considered to be of particular relevance            "E" earlier document but published on or after the international filing date            "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)            "O" document referring to an oral disclosure, use, exhibition or other means            "P" document published prior to the international filing date but later than the priority date claimed         </td> <td style="width: 33%; vertical-align: top;">           "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention            "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone            "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art            "&amp;" document member of the same patent family         </td> <td style="width: 33%;"></td> </tr> </table>			* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family				
Date of the actual completion of the international search 8 February 1995 (08.02.95)		Date of mailing of the international search report 16 Feb 1995 (16.02.95)			
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA  Facsimile No. 06 2853929		Authorized officer  JOHN G. HANSON  Telephone No. (06) 2832262			

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate of the relevant passages	Relevant to Claim No.
X	WO,A, 93/21945 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA et al) 11 November 1993 (11.11.93)	6-7, 12-13
X	WO,A, 93/19783 (THE WHITTIER INSTITUTE FOR DIABETES AND ENDOCRINOLOGY) 14 October 1993 (14.10.93)	6-7, 12-13
X	WO,A, 93/10808 (LA JOLLA CANCER RESEARCH FOUNDATION) 10 June 1993 (10.06.93)	6-7, 12-13
X	WO,A, 93/09800 (LA JOLLA CANCER RESEARCH FOUNDATION et al) 27 May 1993 (27.05.93)	6-7, 12-13
X	WO,A, 92/17206 (THE VICTORIA UNIVERSITY OF MANCHESTER) 15 October 1992 (15.10.92)	6-7, 12-13
X	WO,A, 91/04748 (LA JOLLA CANCER RESEARCH FOUNDATION) 18 April 1991 (18.04.91)	6-7, 12-13
A	AU,A, 27748/92 (MARK CEDRIC GILLIES et al) 3 May 1993 (03.05.93)	

**PCT/AU 94/00694**

Patent Document Cited in Search Report				Patent Family Member			
WO	94/10187	AU	55410/94				
WO	94/09815	AU	56650/94	AU	64166/94	WO	94/23040
WO	94/01124	AU	46681/93				
WO	93/21945	AU	41118/93				
WO	93/19783	AU	39437/93				
WO	93/10808	AU NO	32429/93 942072	EP	616536	FI	942622
WO	93/09800	AU	31385/93	FI	942244	NO	941821
WO	92/17206	AU GB	14368/92 9106678	CA JP	2105652 6506205	EP	585242
WO	91/04748	AU FI	66125/90 921353	CA JP	2065860 5503076	EP NO	494264 921119
AU	27748/92	EP	607275	WO	93/06856		



22

PATENT COOPERATION TREATY  
**PCT**  
INTERNATIONAL PRELIMINARY EXAMINATION REPORT

REC'D 04 JAN 1996

WIPO PCT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P04828-XZ:AMP	<b>FOR FURTHER ACTION</b>	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International application No. <b>PCT/AU 94/00694</b>	International filing date 11 November 1994	Priority Date 19 November 1993
International Patent Classification (IPC) or national classification and IPC  <b>Int. Cl.<sup>6</sup> A61K 38/16, 38/17, 38/18, 38/39, 38/395</b>		
Applicant (1) <b>THE UNIVERSITY OF SYDNEY</b> (2) <b>McAVOY, Johnston William and CHAMBERLAIN, Coral Gwenda</b>		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of **5** sheets, including this cover sheet.
- ☒ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of **1** sheet(s).

3. This report contains indications relating to the following items:

- |      |                                     |   |
|------|-------------------------------------|---|
| I    | <input checked="" type="checkbox"/> | Basis of the report   |
| II   | <input type="checkbox"/>            | Priority  |
| III  | <input type="checkbox"/>            | Non-establishment of opinion with regard to novelty, inventive step and industrial applicability  |
| IV   | <input type="checkbox"/>            | Lack of unity of invention  |
| V    | <input checked="" type="checkbox"/> | Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
| VI   | <input checked="" type="checkbox"/> | Certain documents cited   |
| VII  | <input type="checkbox"/>            | Certain defects in the international application  |
| VIII | <input checked="" type="checkbox"/> | Certain observations on the international application   |

Date of submission of the demand  16 June 1995	Date of completion of the report  18 December 1995
Name and mailing address of the IPEA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No. (06) 285 3929	Authorized Officer  <i>G.A. Jenkins</i> <b>GILLIAN JENKINS</b>  Telephone No. (06) 283 2252

**I. Basis of the report**

1. This report has been drawn on the basis of *(Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.)*:

☐ the international application as originally filed.

☒ the description, pages 1-23, as originally filed,  
pages , filed with the demand,  
pages , filed with the letter of ,  
pages , filed with the letter of .

☒ the claims, Nos. 13, as originally filed,  
Nos. , as amended under Article 19,  
Nos. , filed with the demand,  
Nos. 1-12, filed with the letter of 29 November 1995,  
Nos. , filed with the letter of .

☒ the drawings, sheets/fig 1/1, as originally filed,  
sheets/fig , filed with the demand,  
sheets/fig , filed with the letter of ,  
sheets/fig , filed with the letter of .

2. The amendments have resulted in the cancellation of:

☐ the description, pages

☐ the claims, Nos.

☐ the drawings, sheets/fig

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

4. Additional observations, if necessary:

It should be noted that this opinion covers claims 1-5 and 8-9 which are to methods of treatment of the human or animal body and regarded by some member states of the PCT as excluded subject matter under Rule 67.1(iv).

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. Statement**

Novelty (N)	Claims 1-11	YES
	Claims 12-13	NO
Inventive step (IS)	Claims 1-11	YES
	Claims 12-13	NO
Industrial applicability (IA)	Claims 1-13	YES
	Claims none	NO

**2. Citations and explanations****Claims 1-11**

None of the documents cited in the International Search Report disclose methods of preventing or controlling cataract, cataract-like disorders or aftercataract formation in the eye by administering an inhibitor of TGF $\beta$ . The citations also do not disclose a lens implant coated with TGF $\beta$  inhibitor. The cited documents, however, do disclose formulations comprising TGF $\beta$  inhibitors (such as decorin, biglycan and anti-TGF $\beta$  antibodies) for pharmaceutical use in a range of conditions, including cardiovascular disease, CNS pathologies, scarring, wound healing, fibrotic diseases, arteriosclerosis, diabetic nephropathy etc. Nevertheless, there is no indication that these compositions may be formulated with an ophthalmologically acceptable carrier excluding conventional pharmaceutically acceptable carriers for use in the eye. Claims 1-11 are thus novel and involve an inventive step.

**Claims 12-13**

Claims 12-13 are not clear (see Box VIII) but could be interpreted as merely defining the manufacture of a formulation comprising any TGF $\beta$  inhibitor. These claims would thus lack novelty and inventive step in the light of WO 93/21945, WO 93/19783, WO 93/10808, WO 93/09800, WO 92/17206 and WO 91/04748.

**VI. Certain documents cited****1. Certain published documents (Rule 70.10)**

Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date ( valid claim) (day/month/year)
WO 94/10187	11 May 1994	26 October 1993	30 October 1992
WO 94/09815	11 May 1994	29 October 1993	29 October 1992
WO 94/01124	20 January 1994	8 July 1993	8 July 1992

**2. Non-written disclosures (Rule 70.9)**

Kind of non-written disclosure	Date of non-written disclosure (day/month/year)	Date of written disclosure referring to non-written disclosure (day/month/year)
--------------------------------	--	---

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 12 and 13 lack clarity as they may be interpreted in two possible ways:

- (a) they may define a method of manufacturing a formulation which may need only be suitable for, but not limited to, preventing or controlling cataract or cataract-like disorders; or
- (b) they may define a two-step method in which both the manufacturing and treatment steps are included - in which case the treatment does confer a limitation on the scope of the claim.

Claims

1. A method of preventing or controlling cataract or cataract-like disorders in the eye of a mammalian subject which comprises administering to the subject an effective amount of one or more inhibitors of TGF $\beta$ .
2. A method according to claim 1 wherein the one or more inhibitors of TGF $\beta$  are selected from proteins, glycoproteins and proteoglycans.
3. A method according to claim 2 wherein the protein inhibitors of TGF $\beta$  are selected from antibodies and peptide growth factors.
4. A method according to claim 2 wherein the glycoprotein inhibitors of TGF $\beta$  are selected from  $\alpha_2$ -macroglobulin, laminin and collagen.
5. A method according to claim 2 wherein the proteoglycan inhibitors of TGF $\beta$  are selected from decorin, heparan sulfate proteoglycans and biglycan.
6. An ophthalmological formulation comprising one or more inhibitors of TGF $\beta$  in a pharmaceutically acceptable carrier.
7. An ophthalmological formulation according to claim 6 wherein the inhibitors of TGF $\beta$  are as defined in claim 2, 3, 4 or 5.
8. A method of preventing or controlling "aftercataract" formation in the eye of a mammalian subject following lens implant surgery which comprises implanting in the eye of the subject a lens coated with one or more TGF $\beta$  inhibitors.
9. A method according to claim 8 wherein the TGF $\beta$  inhibitors are as defined in claim 2, 3, 4 or 5.
10. A lens implant coated with one or more TGF $\beta$  inhibitors.
11. A lens implant according to claim 10 coated with one or more TGF $\beta$  inhibitors as defined in claim 2, 3, 4 or 5.
12. The use of inhibitors of TGF $\beta$  in the manufacture of an ophthalmological formulation for preventing or controlling cataract or cataract-like disorders.

replaced by  
figure 3.4